{"gene":"BRF2","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2000,"finding":"TFIIIB50 (BRF2) was identified and cloned as a novel TFIIB homologue that, together with TBP and TFIIIB150 (BDP1), reconstitutes human TFIIIB-alpha activity required for transcription of RNA Pol III genes with upstream (gene-external) promoter elements. This established that higher eukaryotes evolved two distinct TFIIB-related factors (BRF1 and BRF2) that mediate promoter selectivity by RNA Pol III.","method":"Cloning, biochemical reconstitution of TFIIIB-alpha activity in vitro, in vitro transcription assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of transcription activity with purified components, original identification study","pmids":["11121026"],"is_preprint":false},{"year":2001,"finding":"BRFU (BRF2) is directly recruited to the TATA-box of Pol III-type snRNA gene promoters in a TBP-dependent manner. BRF2 in turn stabilizes TBP on TATA-containing template and extends the TBP footprint both upstream and downstream of the TATA element. The core domain of TBP is sufficient for BRF2·TBP·DNA complex formation. BRF2 has no intrinsic specificity for sequences flanking the TATA-box, indicating polymerase recruitment is not determined solely by TATA-box sequence context.","method":"DNase I footprinting, gel mobility shift assays, in vitro transcription, domain mapping by truncation/mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical methods (footprinting, EMSA, mutagenesis, in vitro transcription) in a single study","pmids":["11564744"],"is_preprint":false},{"year":2007,"finding":"Human Maf1 negatively regulates RNA Pol III transcription via both TFIIB family members BRF1 and BRF2. Maf1 repression of Pol III transcription occurs through TFIIIB, specifically targeting BRF1 and BRF2.","method":"RNA Pol III luciferase reporter assay, in vivo transcription assays, co-immunoprecipitation","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter assay with in vivo validation, single lab","pmids":["17505538"],"is_preprint":false},{"year":2008,"finding":"BRF2 and BRF1 are differentially expressed in cancer cell lines. BRF2 protein expression levels correlate with U6 promoter activity (BRF2-dependent Pol III transcription), while BRF1 protein levels did not correlate with BRF1-dependent transcription. The BRF2 promoter is more active than the BRF1 promoter across all cancer cell lines tested, suggesting deregulation of BRF2 expression is a key mechanism for observed upregulation of Pol III transcription in cancer.","method":"Quantitative RT-PCR, western blotting, promoter-reporter assays, in vitro transcription","journal":"BMC molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods (promoter activity, protein quantification, transcription assays), single lab","pmids":["18700021"],"is_preprint":false},{"year":2010,"finding":"BRF2 was identified as a lineage-specific oncogene in lung squamous cell carcinoma. Focal amplification of BRF2 at chromosome 8p12 drives increased Pol III-mediated transcription of snRNAs. Ectopic BRF2 expression in human bronchial epithelial cells induced cellular transformation, while RNAi-mediated BRF2 knockdown suppressed growth and colony formation of SqCC cells overexpressing BRF2 but not adenocarcinoma cells.","method":"Comparative genomic hybridization, gene expression microarrays, RNAi knockdown, ectopic overexpression with colony formation assays, integrative genomics","journal":"PLoS medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (CGH, expression arrays, functional gain/loss-of-function), replicated across >330 clinical samples","pmids":["20668658"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of a human BRF2–TBP complex bound to natural Pol III promoters (U6 snRNA and selenocysteine tRNA genes) revealed a detailed molecular view of interactions at BRF2-dependent Pol III promoters and showed general structural and functional conservation between human Pol II and Pol III pre-initiation complexes. Crucially, BRF2 harbors a redox-sensing module: under oxidative stress conditions, a disulfide bond forms within BRF2 that specifically regulates Pol III transcriptional output in living cells, establishing BRF2 as a central redox-sensing transcription factor involved in the oxidative stress pathway.","method":"X-ray crystallography, in vitro transcription assays, mutagenesis of redox-sensing cysteines, cell-based oxidative stress assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with functional mutagenesis and cell-based validation, multiple orthogonal methods","pmids":["26638071"],"is_preprint":false},{"year":2015,"finding":"The soy isoflavone daidzein specifically stimulates BRF2 expression in ER-positive breast cancer cells through two mechanisms: stabilization of BRF2 mRNA and selective demethylation of the BRF2 promoter. BRF2 induction is accompanied by increased levels of BRF2-regulated non-coding RNAs. These effects are ER-dependent, as they are absent in ER-negative breast cancer cells.","method":"qRT-PCR, western blotting, mRNA stability assays, promoter methylation analysis, 5-azacytidine demethylation experiments","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (mRNA stability, methylation, rescue with demethylating agent), single lab","pmids":["26573593"],"is_preprint":false},{"year":2017,"finding":"BRF2 acts as a master switch of the oxidative stress response and interplays with the Nrf2/Keap1 pathway. The redox-sensing module of BRF2 integrates oxidative stress signals to regulate Pol III transcription, placing BRF2 downstream of or in parallel with Nrf2/Keap1 signaling.","method":"Review/synthesis of structural and functional data (based on prior experimental work from PMID:26638071)","journal":"Transcription","confidence":"Medium","confidence_rationale":"Tier 3 — review synthesizing prior experimental findings; no new primary experiments","pmids":["28854119"],"is_preprint":false},{"year":2021,"finding":"BRF2 promotes LUAD cell proliferation and metastasis via the MAPK/ERK signaling pathway. Let-7b-3p directly targets the 3' UTR of BRF2 mRNA to suppress its expression, and BRF2 knockdown phenocopies let-7b-3p overexpression. Transcriptome sequencing and western blot analyses confirmed BRF2-mediated activation of MAPK/ERK signaling.","method":"Dual-luciferase reporter assay (miRNA target validation), transcriptome sequencing, western blotting, MTT/colony formation/Transwell assays, in vivo xenograft","journal":"Translational lung cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — direct target validation by luciferase assay, transcriptome sequencing, in vivo rescue, single lab","pmids":["34012797"],"is_preprint":false},{"year":2021,"finding":"BRF2 is a novel player in the DNA damage response pathway. BRF2 overexpression promotes cancer cell survival under oxidative stress, and treatment with bexarotene reduces oxidative stress-induced BRF2 levels, decreasing cellular proliferation. BRF2 binds the TBP-DNA complex, and virtual screening identified compounds disrupting the BRF2-TBP-DNA interface.","method":"Virtual screening, molecular dynamics simulation, cell viability assays, western blotting with oxidative stress induction (tBHQ)","journal":"Cancers","confidence":"Low","confidence_rationale":"Tier 3-4 — primarily computational with limited cell-based validation, single lab, no direct mechanistic reconstitution of DNA damage role","pmids":["34359683"],"is_preprint":false},{"year":2023,"finding":"MALAT1 acts as a competitive endogenous RNA (ceRNA) to sponge miR-1-3p, thereby upregulating BRF2 expression in HCC. BRF2 knockdown inhibits HCC progression by activating the LKB1/AMPK signaling pathway, and BRF2 overexpression reverses the inhibitory effects of MALAT1 knockdown.","method":"Dual-luciferase reporter assay, qRT-PCR, western blotting, CCK-8/colony formation/Transwell assays, flow cytometry, xenograft tumor model","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 — direct ceRNA mechanism validated by luciferase assay, pathway confirmed by western blot and rescue experiments, in vivo validation","pmids":["37653482"],"is_preprint":false},{"year":2023,"finding":"BRF2 promotes HCC invasion and metastasis through the Wnt/β-catenin signaling pathway. miR-409-3p was identified as binding to the 3' UTR of BRF2 and downregulating its expression. BRF2 depletion suppressed HCC metastasis and invasion.","method":"Luciferase activity assay (miRNA target validation), bioinformatic pathway analysis, siRNA knockdown, invasion/migration assays","journal":"Cancer cell international","confidence":"Low","confidence_rationale":"Tier 3 — Wnt/β-catenin link is bioinformatic only; direct mechanistic link between BRF2 and pathway not experimentally established beyond knockdown phenotype","pmids":["36927769"],"is_preprint":false},{"year":2025,"finding":"Biallelic loss-of-function variants in BRF2 cause a novel neurodevelopmental syndrome with craniofacial anomalies and perinatal death. In silico 3D modeling and functional analyses showed that patient variants impair BRF2-dependent RNA Pol III transcription (altered target loci occupancy). Zebrafish brf2 knockdown recapitulated craniofacial malformations and behavioral deficits, which were rescued by wild-type human BRF2 mRNA but not mutant mRNA.","method":"Whole-exome sequencing, in silico 3D structural modeling, ChIP/occupancy assays (target loci), zebrafish morpholino knockdown with mRNA rescue","journal":"Genome medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (structural modeling, functional occupancy assays, zebrafish rescue with wild-type vs. mutant mRNA), independent families","pmids":["40229899"],"is_preprint":false},{"year":2025,"finding":"Biallelic BRF2 variants causing multisystem anomalies and primary immunodeficiency disrupt BRF2-dependent RNA Pol III transcription of redox-regulating genes GPX1 and GPX4 (glutathione peroxidases), establishing a pathogenic link between BRF2 dysfunction and disrupted redox homeostasis. Compound heterozygous variants are predicted to disrupt BRF2 interaction with TBP.","method":"Whole-exome sequencing, single-cell RNA sequencing, functional analysis of BRF2-dependent Pol III transcription in patient cells, western blotting","journal":"Molecular therapy : the journal of the American Society of Gene Therapy","confidence":"Medium","confidence_rationale":"Tier 2 — functional transcription assay in patient cells identifying specific target genes (GPX1/GPX4), single family/lab","pmids":["40781771"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of the full-length SNAPc-containing RNA Pol III pre-initiation complex (PIC) assembled on the U6 snRNA promoter in open and melting states (3.2–4.2 Å resolution) revealed the molecular architecture of the Brf2-containing TFIIIB complex within the PIC. Comparative analysis revealed unexpected structural differences from the yeast PIC and defined the molecular basis of selective, structurally distinct SNAPc engagement within Pol III versus Pol II PICs. Crosslinking mass spectrometry localized SNAPC2 and SNAPC5 subunits in proximity to the promoter DNA.","method":"Cryo-EM structure determination, crosslinking mass spectrometry, comparative structural analysis","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures at high resolution with crosslinking MS orthogonal validation","pmids":["bio_10.1101_2024.09.10.612236"],"is_preprint":true}],"current_model":"BRF2 (TFIIB-related factor 2) is a vertebrate-specific subunit of the TFIIIB-alpha complex that recruits RNA Polymerase III to type III gene-external promoters (including U6 snRNA and selenocysteine tRNA genes) through TBP-dependent binding to TATA-box elements; it harbors a redox-sensing disulfide module that specifically upregulates Pol III transcriptional output under oxidative stress, placing BRF2 as a central integrator of the Nrf2/Keap1 oxidative stress pathway, and its genetic amplification drives oncogenic transformation by increasing Pol III-mediated small RNA synthesis, while loss-of-function biallelic variants impair transcription of redox-protective genes (GPX1/GPX4) causing neurodevelopmental syndromes with craniofacial anomalies and immunodeficiency."},"narrative":{"teleology":[{"year":2000,"claim":"Identification of BRF2 as a second TFIIB-related factor in humans resolved how vertebrate RNA Pol III discriminates between gene-internal and gene-external promoter architectures, establishing that two distinct TFIIIB complexes exist.","evidence":"Cloning and biochemical reconstitution of TFIIIB-α activity with purified BRF2, TBP, and BDP1 in vitro","pmids":["11121026"],"confidence":"High","gaps":["No structural information on how BRF2 differs from BRF1 at the atomic level","In vivo promoter occupancy not yet demonstrated"]},{"year":2001,"claim":"Demonstration that BRF2 is recruited to the TATA-box via TBP and stabilizes TBP on DNA defined the minimal assembly pathway of the TFIIIB-α complex on type III promoters.","evidence":"DNase I footprinting, gel mobility shift assays, truncation/mutagenesis, and in vitro transcription","pmids":["11564744"],"confidence":"High","gaps":["Role of BDP1 in the ternary complex not structurally resolved","No information on how SNAPc coordinates with BRF2-TBP"]},{"year":2007,"claim":"Showing that Maf1 represses Pol III transcription through both BRF1 and BRF2 established a conserved negative regulatory mechanism acting at the TFIIIB level.","evidence":"RNA Pol III luciferase reporter assays, in vivo transcription assays, co-immunoprecipitation","pmids":["17505538"],"confidence":"Medium","gaps":["Direct physical interaction between Maf1 and BRF2 not mapped at residue level","Single-lab finding without independent replication"]},{"year":2010,"claim":"Identification of BRF2 as a lineage-specific oncogene amplified in lung squamous cell carcinoma established that deregulated Pol III transcription of small RNAs is sufficient to drive cellular transformation.","evidence":"Array CGH across >330 clinical samples, ectopic BRF2 expression inducing transformation of bronchial epithelial cells, RNAi knockdown suppressing growth of SqCC cells","pmids":["20668658"],"confidence":"High","gaps":["Specific Pol III transcript repertoire mediating transformation not defined","Whether BRF2 amplification cooperates with other 8p12 co-amplified genes unclear"]},{"year":2015,"claim":"Crystal structures of the BRF2–TBP complex on natural Pol III promoters revealed a redox-sensing disulfide module within BRF2 that regulates Pol III output under oxidative stress, establishing BRF2 as the first transcription factor integrating redox signals directly into Pol III activity.","evidence":"X-ray crystallography, cysteine mutagenesis, in vitro transcription, and cell-based oxidative stress assays","pmids":["26638071"],"confidence":"High","gaps":["Identity of the upstream oxidant or reductant that modulates the disulfide in vivo not determined","Whether the redox switch operates at all BRF2-dependent promoters or selectively is unknown"]},{"year":2015,"claim":"Demonstration that daidzein induces BRF2 expression through mRNA stabilization and promoter demethylation in ER-positive breast cancer cells revealed an estrogen receptor-dependent epigenetic axis controlling BRF2 levels.","evidence":"mRNA stability assays, promoter methylation analysis, 5-azacytidine rescue in ER-positive vs. ER-negative cell lines","pmids":["26573593"],"confidence":"Medium","gaps":["Direct ER binding to the BRF2 promoter not demonstrated","In vivo relevance of dietary isoflavone exposure to BRF2 regulation not established"]},{"year":2021,"claim":"Identification of miRNA-mediated post-transcriptional regulation of BRF2 (let-7b-3p in LUAD, miR-1-3p via MALAT1 ceRNA in HCC) and downstream signaling through MAPK/ERK and LKB1/AMPK pathways extended the oncogenic role of BRF2 beyond Pol III transcription to broader proliferative and metastatic signaling networks.","evidence":"Dual-luciferase target validation, transcriptome sequencing, xenograft models, pathway rescue experiments","pmids":["34012797","37653482"],"confidence":"Medium","gaps":["Whether MAPK/ERK activation is a direct or indirect consequence of BRF2-driven Pol III transcript changes is unresolved","The specific Pol III transcripts mediating these signaling effects remain unidentified"]},{"year":2025,"claim":"Discovery that biallelic BRF2 loss-of-function variants cause a neurodevelopmental syndrome with craniofacial anomalies, immunodeficiency, and impaired transcription of GPX1/GPX4 established BRF2 as a Mendelian disease gene and linked its redox-sensing function to human developmental biology.","evidence":"Whole-exome sequencing in independent families, ChIP/occupancy assays in patient cells, zebrafish morpholino knockdown rescued by wild-type but not mutant human BRF2 mRNA, single-cell RNA-seq identifying GPX1/GPX4 as affected targets","pmids":["40229899","40781771"],"confidence":"High","gaps":["Full spectrum of BRF2-dependent Pol III transcripts disrupted in patient cells not catalogued","Whether immunodeficiency is driven by GPX-dependent redox failure or broader Pol III transcript deficiency is unclear","No mouse model yet reported"]},{"year":null,"claim":"Major open questions include the complete repertoire of BRF2-dependent Pol III transcripts in different tissues, the identity of the physiological redox regulators controlling the BRF2 disulfide switch in vivo, and the structural basis of the full human SNAPc–TFIIIB–Pol III pre-initiation complex at atomic resolution.","evidence":"","pmids":[],"confidence":"High","gaps":["No published high-resolution structure of the complete human BRF2-containing PIC from a peer-reviewed journal","Tissue-specific BRF2-dependent transcriptome not mapped","Mechanism connecting BRF2 redox state to specific downstream transcript selectivity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140223","term_label":"general transcription initiation factor activity","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,12,13]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,5,12]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,5,12,13]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[5,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,8,10]}],"complexes":["TFIIIB-α (BRF2–TBP–BDP1)"],"partners":["TBP","BDP1","MAF1","SNAPC1","SNAPC2","SNAPC5"],"other_free_text":[]},"mechanistic_narrative":"BRF2 is a vertebrate-specific subunit of the TFIIIB-α complex that, together with TBP and BDP1, directs RNA Polymerase III to gene-external (type III) promoters including U6 snRNA and selenocysteine tRNA genes, thereby controlling the synthesis of essential small non-coding RNAs [PMID:11121026, PMID:11564744]. BRF2 binds DNA-bound TBP in a TATA-box-dependent manner, extending the TBP footprint to stabilize the pre-initiation complex, and harbors a redox-sensing disulfide module whose oxidation-state switch specifically upregulates Pol III transcriptional output under oxidative stress, functionally linking it to the Nrf2/Keap1 pathway [PMID:26638071]. Focal amplification of BRF2 at 8p12 acts as a lineage-specific oncogene in lung squamous cell carcinoma by increasing Pol III-dependent snRNA synthesis, and BRF2 overexpression promotes proliferation and metastasis in additional cancer types through MAPK/ERK and other signaling axes [PMID:20668658, PMID:34012797]. Biallelic loss-of-function BRF2 variants cause a neurodevelopmental syndrome with craniofacial anomalies, immunodeficiency, and impaired transcription of redox-protective genes GPX1 and GPX4 [PMID:40229899, PMID:40781771]."},"prefetch_data":{"uniprot":{"accession":"Q9HAW0","full_name":"Transcription factor IIIB 50 kDa subunit","aliases":["B-related factor 2","BRF-2","hBRFU"],"length_aa":419,"mass_kda":46.5,"function":"General activator of RNA polymerase III transcription. Factor exclusively required for RNA polymerase III transcription of genes with promoter elements upstream of the initiation sites (PubMed:11040218, PubMed:11121026, PubMed:11564744, PubMed:26638071). Contributes to the regulation of gene expression; functions as activator in the absence of oxidative stress (PubMed:26638071). Down-regulates expression of target genes in response to oxidative stress (PubMed:26638071). Overexpression protects cells against apoptosis in response to oxidative stress (PubMed:26638071)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9HAW0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BRF2","classification":"Common Essential","n_dependent_lines":1206,"n_total_lines":1208,"dependency_fraction":0.9983443708609272},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BRF2","total_profiled":1310},"omim":[{"mim_id":"607013","title":"BRF2 SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR; BRF2","url":"https://www.omim.org/entry/607013"},{"mim_id":"607012","title":"B-DOUBLE PRIME 1, SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR IIIB; BDP1","url":"https://www.omim.org/entry/607012"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoli","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRF2"},"hgnc":{"alias_symbol":["FLJ11052","BRFU","TFIIIB50"],"prev_symbol":[]},"alphafold":{"accession":"Q9HAW0","domains":[{"cath_id":"-","chopping":"14-58","consensus_level":"high","plddt":70.9558,"start":14,"end":58},{"cath_id":"1.10.472.10","chopping":"66-167","consensus_level":"high","plddt":95.5782,"start":66,"end":167},{"cath_id":"1.10.472.10","chopping":"169-320","consensus_level":"high","plddt":93.6986,"start":169,"end":320}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAW0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAW0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HAW0-F1-predicted_aligned_error_v6.png","plddt_mean":84.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRF2","jax_strain_url":"https://www.jax.org/strain/search?query=BRF2"},"sequence":{"accession":"Q9HAW0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HAW0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HAW0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HAW0"}},"corpus_meta":[{"pmid":"26638071","id":"PMC_26638071","title":"Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638071","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20668658","id":"PMC_20668658","title":"Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.","date":"2010","source":"PLoS medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20668658","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11121026","id":"PMC_11121026","title":"A stable complex of a novel transcription factor IIB- related factor, human TFIIIB50, and associated proteins mediate selective transcription by RNA polymerase III of genes with upstream promoter elements.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11121026","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21518452","id":"PMC_21518452","title":"RNA polymerase III transcription in cancer: the BRF2 connection.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21518452","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30618167","id":"PMC_30618167","title":"Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30618167","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17505538","id":"PMC_17505538","title":"Human Maf1 negatively regulates RNA polymerase III transcription via the TFIIB family members Brf1 and Brf2.","date":"2007","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17505538","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26573593","id":"PMC_26573593","title":"Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26573593","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29025258","id":"PMC_29025258","title":"MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line.","date":"2017","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29025258","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18700021","id":"PMC_18700021","title":"Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells.","date":"2008","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18700021","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34012797","id":"PMC_34012797","title":"Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma.","date":"2021","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34012797","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11564744","id":"PMC_11564744","title":"BRFU, a TFIIB-like factor, is directly recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with TATA-binding protein.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11564744","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9020796","id":"PMC_9020796","title":"Apolipoprotein B gene regulatory factor-2 (BRF-2) is structurally and immunologically highly related to hepatitis B virus X associated protein-1 (XAP-1).","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9020796","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37653482","id":"PMC_37653482","title":"MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37653482","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36927769","id":"PMC_36927769","title":"BRF2 is mediated by microRNA-409-3p and promotes invasion and metastasis of HCC through the Wnt/β-catenin pathway.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36927769","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34359683","id":"PMC_34359683","title":"Targeting BRF2 in Cancer Using Repurposed Drugs.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34359683","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32705258","id":"PMC_32705258","title":"Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32705258","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28854119","id":"PMC_28854119","title":"New tricks for an old dog: Brf2-dependent RNA Polymerase III transcription in oxidative stress and cancer.","date":"2017","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/28854119","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30182305","id":"PMC_30182305","title":"BRF2 as a promising indicator for radical lymph-node dissection surgery in patients with cN0 squamous cell carcinoma of the middle thoracic esophagus.","date":"2018","source":"Surgery today","url":"https://pubmed.ncbi.nlm.nih.gov/30182305","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1620125","id":"PMC_1620125","title":"Transcriptional regulation of the apolipoprotein B100 gene: purification and characterization of trans-acting factor BRF-2.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1620125","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31277948","id":"PMC_31277948","title":"Double mutation of BRF1 and BRF2 leads to sterility in Arabidopsis thaliana.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31277948","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40229899","id":"PMC_40229899","title":"Bi-allelic variants in BRF2 are associated with perinatal death and craniofacial anomalies.","date":"2025","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40229899","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40781771","id":"PMC_40781771","title":"Biallelic BRF2 mutations disrupt redox homeostasis as etiological factors in syndromic immunodeficiency and developmental disorders.","date":"2025","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40781771","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37705251","id":"PMC_37705251","title":"Targeting BRF2: insights from in silico screening and molecular dynamic simulations.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37705251","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.10.612236","title":"Structural insights into distinct mechanisms of RNA polymerase II and III recruitment to snRNA promoters","date":"2024-09-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.10.612236","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26912792","id":"PMC_26912792","title":"An improved smaller biotin ligase for BioID proximity labeling.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26912792","citation_count":665,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29395067","id":"PMC_29395067","title":"High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395067","citation_count":580,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21151128","id":"PMC_21151128","title":"Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21151128","citation_count":555,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24255178","id":"PMC_24255178","title":"Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24255178","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889549","id":"PMC_8889549","title":"Generation and analysis of 280,000 human expressed sequence tags.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889549","citation_count":376,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14981510","id":"PMC_14981510","title":"Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d.","date":"2004","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14981510","citation_count":302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27173435","id":"PMC_27173435","title":"An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27173435","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26673895","id":"PMC_26673895","title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26673895","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17979178","id":"PMC_17979178","title":"A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes.","date":"2007","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/17979178","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18461144","id":"PMC_18461144","title":"Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18461144","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21278925","id":"PMC_21278925","title":"The roles of TTP and BRF proteins in regulated mRNA decay.","date":"2011","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/21278925","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28860350","id":"PMC_28860350","title":"Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.","date":"2017","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/28860350","citation_count":98,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32694731","id":"PMC_32694731","title":"Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694731","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25106868","id":"PMC_25106868","title":"ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25106868","citation_count":78,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26972000","id":"PMC_26972000","title":"Substrate-Trapped Interactors of PHD3 and FIH Cluster in Distinct Signaling Pathways.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26972000","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31048690","id":"PMC_31048690","title":"Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31048690","citation_count":76,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29053956","id":"PMC_29053956","title":"Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29053956","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33632712","id":"PMC_33632712","title":"Genomic evolution and diverse models of systemic metastases in colorectal cancer.","date":"2021","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/33632712","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29426877","id":"PMC_29426877","title":"ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent and p53-independent manner.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29426877","citation_count":62,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13583,"output_tokens":2538,"usd":0.03941},"stage2":{"model":"claude-opus-4-6","input_tokens":5872,"output_tokens":2037,"usd":0.120428},"total_usd":0.389483,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":25912,"output_tokens":5054,"usd":0.076773},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7703,"output_tokens":2536,"usd":0.152872}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of human Brf2-TBP complex bound to natural promoters revealed detailed molecular interactions at Brf2-dependent Pol III promoters, and structural/functional studies uncovered a Brf2 redox-sensing module capable of specifically regulating Pol III transcriptional output in living cells in response to oxidative stress.\",\n      \"method\": \"X-ray crystallography, structural analysis, functional studies in living cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional validation in cells, published in high-impact journal\",\n      \"pmids\": [\"26638071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BRF2 (TFIIIB50) was identified as a novel TFIIB-related factor that, together with TBP and TFIIIB150, reconstitutes human TFIIIB-alpha activity required for selective transcription by RNA Pol III from gene-external (upstream) promoter elements, distinct from BRF1-containing TFIIIB-beta which mediates gene-internal promoter transcription.\",\n      \"method\": \"Biochemical reconstitution, cloning, and in vitro transcription assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution of TFIIIB-alpha activity with defined components\",\n      \"pmids\": [\"11121026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BRFU (BRF2) is directly recruited to the TATA-box of Pol III snRNA gene promoters through TBP-dependent interaction; BRFU stabilizes TBP on TATA-containing template and extends the TBP footprint both upstream and downstream of the TATA element. Specific amino acid residues in TBP and domains of BRFU mediating this interaction were mapped.\",\n      \"method\": \"DNase I footprinting, gel mobility shift assay, domain mapping, in vitro transcription\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and footprinting, multiple orthogonal methods\",\n      \"pmids\": [\"11564744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Human Maf1 negatively regulates RNA Pol III transcription via TFIIIB, specifically through the TFIIB family members Brf1 and Brf2, establishing Brf2 as a direct target of Maf1-mediated repression.\",\n      \"method\": \"In vivo RNA Pol III luciferase assay, functional repression assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay in vivo demonstrating Maf1 acts through Brf2, single lab\",\n      \"pmids\": [\"17505538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRF2 overexpression in human bronchial epithelial cells induced a transformed phenotype and increased expression of snRNAs involved in RNA splicing; RNAi-mediated knockdown suppressed growth and colony formation of SqCC cells overexpressing BRF2, establishing BRF2 as an oncogenic driver of Pol III-mediated transcription.\",\n      \"method\": \"Ectopic overexpression, RNAi knockdown, colony formation assay, integrative genomics\",\n      \"journal\": \"PLoS medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with defined cellular phenotypes, multiple cancer cohorts\",\n      \"pmids\": [\"20668658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRF2 was shown to be a novel player in the DNA damage response pathway; bexarotene treatment reduced oxidative stress-induced BRF2 levels and decreased cancer cell proliferation, suggesting BRF2 links redox signaling to the DNA damage response.\",\n      \"method\": \"Drug treatment, western blotting, cell proliferation assay, virtual screening/molecular dynamics\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, indirect mechanistic link between BRF2 and DNA damage response\",\n      \"pmids\": [\"34359683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRF2 knockdown in HCC cells activated the LKB1/AMPK signaling pathway, inhibiting HCC progression; MALAT1 acts as a competitive endogenous RNA sponging miR-1-3p to upregulate BRF2, establishing a MALAT1/miR-1-3p/BRF2/LKB1/AMPK regulatory axis.\",\n      \"method\": \"siRNA knockdown, dual-luciferase reporter assay, western blotting, xenograft tumor model\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pathway placement relies on western blot without direct epistasis\",\n      \"pmids\": [\"37653482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"miR-409-3p was shown to bind the 3' UTR of BRF2 and downregulate its expression; BRF2 depletion suppressed HCC metastasis and invasion, and bioinformatic analysis suggested BRF2 functions via the Wnt/β-catenin signaling pathway.\",\n      \"method\": \"Luciferase reporter assay, siRNA knockdown, bioinformatic analysis\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — Wnt pathway link is bioinformatic only; miR-409-3p targeting validated by luciferase assay\",\n      \"pmids\": [\"36927769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Biallelic BRF2 variants identified in patients with multisystem anomalies cause defective BRF2-dependent RNA Pol III transcription; functional analyses in human cells expressing the variants demonstrated impaired transcription of redox-regulating genes GPX1 and GPX4, establishing a pathogenic link between BRF2 dysfunction and disrupted redox homeostasis.\",\n      \"method\": \"Whole-exome sequencing, single-cell RNA sequencing, functional assays in human cells expressing variants\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional validation in human cells with patient variants showing impaired Pol III transcription of specific targets\",\n      \"pmids\": [\"40781771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Biallelic BRF2 variants cause reduced occupancy at target loci; zebrafish knocked down for brf2 exhibited craniofacial malformations and neurological defects that were rescued by human wild-type but not mutant BRF2 mRNA, demonstrating functional conservation and variant deleteriousness in vivo.\",\n      \"method\": \"In silico 3D modelling, ChIP/occupancy assays, zebrafish morpholino knockdown with mRNA rescue\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — zebrafish rescue experiment with wild-type vs. mutant human BRF2, functional validation in vivo\",\n      \"pmids\": [\"40229899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of the full-length SNAPc-containing Pol III pre-initiation complex (PIC) assembled on the U6 snRNA promoter (open and melting states at 3.2–4.2 Å) revealed the molecular basis of Brf2-containing TFIIIB complex assembly and how SNAPc selectively and structurally distinctly engages within Pol III vs Pol II PICs; crosslinking mass spectrometry localized SNAPC2 and SNAPC5 subunits near the promoter DNA.\",\n      \"method\": \"Cryo-EM structure determination, crosslinking mass spectrometry\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure at near-atomic resolution with orthogonal crosslinking MS validation\",\n      \"pmids\": [\"bio_10.1101_2024.09.10.612236\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BRF2 (TFIIIB50/BRFU) is a vertebrate-specific TFIIB-like core transcription factor that is recruited to the TATA-box of type III gene-external Pol III promoters (e.g., U6 snRNA, selenocysteine tRNA, RNase P RNA) through direct TBP interaction, where it stabilizes the pre-initiation complex and recruits RNA Pol III; crucially, BRF2 contains a redox-sensing module that responds to oxidative stress to modulate Pol III transcriptional output, including expression of redox-regulating selenoproteins (GPX1/GPX4), and its overexpression or genetic activation drives oncogenesis in lung squamous cell carcinoma and other cancers, while loss-of-function biallelic variants cause neurodevelopmental disease and disrupted redox homeostasis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEEP papers only.\n\n**Classification:**\n\n- [1] KEEP — BRF2 (TFIIB-related factor 2, RNA Pol III subunit), crystal structure, redox sensing\n- [2] KEEP — BRF2 oncogene in lung SqCC\n- [3] KEEP — TFIIIB50/BRF2 identification and characterization\n- [4] KEEP — BRF2 in cancer/Pol III transcription review\n- [5] EXCLUDE — Case (B): describes lncRNA MNX1-AS1/miR-527/BRF2 axis; while BRF2 is mentioned as a target, this is primarily about the lncRNA mechanism, but BRF2 protein function itself is noted. Actually, this does contain mechanistic info about BRF2 as a downstream effector — KEEP marginally, but the mechanistic finding is just that BRF2 expression promotes proliferation/migration when rescued.\n- [6] KEEP — Maf1 regulation of BRF2\n- [7] KEEP — daidzein induction of BRF2 via promoter demethylation/mRNA stabilization\n- [8] KEEP — miR-373 targets BRF2; BRF2 knockdown phenotype\n- [9] KEEP — Brf1/Brf2 differential expression, promoter activity\n- [10] KEEP — BRF2-mediated MAPK/ERK pathway\n- [11] KEEP — BRFU/BRF2, TBP interaction, promoter recruitment\n- [12] EXCLUDE — Case (A): \"BRF-2\" here is apolipoprotein B regulatory factor-2 (XAP-1/UV-DDB), completely different protein (120 kDa, rat liver, apoB gene regulation) — NOT the RNA Pol III TFIIB-related factor BRF2\n- [13] KEEP — MALAT1/miR-1-3p/BRF2/LKB1/AMPK axis in HCC\n- [14] KEEP — miR-409-3p/BRF2/Wnt/β-catenin pathway in HCC\n- [15] KEEP — BRF2 in DNA damage response; bexarotene as inhibitor\n- [16] KEEP — BRF2 silencing, Akt/EGFR pathway effects\n- [17] KEEP — Review of Brf2 redox/Nrf2/Keap1 interplay\n- [18] EXCLUDE — Pure clinical/prognostic study, no mechanistic findings\n- [19] EXCLUDE — Case (A): \"BRF-2\" is apoB regulatory factor-2, completely different protein\n- [20] EXCLUDE — Case (A) SYMBOL COLLISION: Arabidopsis BRF1/BRF2 in plant reproduction — plant ortholog with incompatible cellular context\n- [21] KEEP — Biallelic BRF2 variants, craniofacial anomalies, zebrafish functional validation\n- [22] KEEP — Biallelic BRF2 variants, immunodeficiency, redox homeostasis (GPX1/GPX4)\n- [23] KEEP — In silico/molecular docking targeting BRF2 molecular pin motif\n- [24] KEEP (preprint) — Cryo-EM structure of SNAPc-containing Pol III PIC with Brf2-TFIIIB\n\n**Additional gene2pubmed papers:**\n- Most are large proteomics/interactome studies not specifically about BRF2 mechanism — EXCLUDE as they don't contain BRF2-specific mechanistic findings\n- [22] TTP/BRF proteins — Case (A): BRF-1 and BRF-2 here are ZFP36L1/ZFP36L2 (ARE-binding proteins), NOT RNA Pol III BRF2 — EXCLUDE\n- [25], [27], [29], [30] — ZFP36L2 papers — EXCLUDE (different gene)\n- Others are generic genomics/proteomics resources — no BRF2-specific mechanistic content\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"TFIIIB50 (BRF2) was identified and cloned as a novel TFIIB homologue that, together with TBP and TFIIIB150 (BDP1), reconstitutes human TFIIIB-alpha activity required for transcription of RNA Pol III genes with upstream (gene-external) promoter elements. This established that higher eukaryotes evolved two distinct TFIIB-related factors (BRF1 and BRF2) that mediate promoter selectivity by RNA Pol III.\",\n      \"method\": \"Cloning, biochemical reconstitution of TFIIIB-alpha activity in vitro, in vitro transcription assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of transcription activity with purified components, original identification study\",\n      \"pmids\": [\"11121026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BRFU (BRF2) is directly recruited to the TATA-box of Pol III-type snRNA gene promoters in a TBP-dependent manner. BRF2 in turn stabilizes TBP on TATA-containing template and extends the TBP footprint both upstream and downstream of the TATA element. The core domain of TBP is sufficient for BRF2·TBP·DNA complex formation. BRF2 has no intrinsic specificity for sequences flanking the TATA-box, indicating polymerase recruitment is not determined solely by TATA-box sequence context.\",\n      \"method\": \"DNase I footprinting, gel mobility shift assays, in vitro transcription, domain mapping by truncation/mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods (footprinting, EMSA, mutagenesis, in vitro transcription) in a single study\",\n      \"pmids\": [\"11564744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Human Maf1 negatively regulates RNA Pol III transcription via both TFIIB family members BRF1 and BRF2. Maf1 repression of Pol III transcription occurs through TFIIIB, specifically targeting BRF1 and BRF2.\",\n      \"method\": \"RNA Pol III luciferase reporter assay, in vivo transcription assays, co-immunoprecipitation\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter assay with in vivo validation, single lab\",\n      \"pmids\": [\"17505538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRF2 and BRF1 are differentially expressed in cancer cell lines. BRF2 protein expression levels correlate with U6 promoter activity (BRF2-dependent Pol III transcription), while BRF1 protein levels did not correlate with BRF1-dependent transcription. The BRF2 promoter is more active than the BRF1 promoter across all cancer cell lines tested, suggesting deregulation of BRF2 expression is a key mechanism for observed upregulation of Pol III transcription in cancer.\",\n      \"method\": \"Quantitative RT-PCR, western blotting, promoter-reporter assays, in vitro transcription\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (promoter activity, protein quantification, transcription assays), single lab\",\n      \"pmids\": [\"18700021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRF2 was identified as a lineage-specific oncogene in lung squamous cell carcinoma. Focal amplification of BRF2 at chromosome 8p12 drives increased Pol III-mediated transcription of snRNAs. Ectopic BRF2 expression in human bronchial epithelial cells induced cellular transformation, while RNAi-mediated BRF2 knockdown suppressed growth and colony formation of SqCC cells overexpressing BRF2 but not adenocarcinoma cells.\",\n      \"method\": \"Comparative genomic hybridization, gene expression microarrays, RNAi knockdown, ectopic overexpression with colony formation assays, integrative genomics\",\n      \"journal\": \"PLoS medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (CGH, expression arrays, functional gain/loss-of-function), replicated across >330 clinical samples\",\n      \"pmids\": [\"20668658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of a human BRF2–TBP complex bound to natural Pol III promoters (U6 snRNA and selenocysteine tRNA genes) revealed a detailed molecular view of interactions at BRF2-dependent Pol III promoters and showed general structural and functional conservation between human Pol II and Pol III pre-initiation complexes. Crucially, BRF2 harbors a redox-sensing module: under oxidative stress conditions, a disulfide bond forms within BRF2 that specifically regulates Pol III transcriptional output in living cells, establishing BRF2 as a central redox-sensing transcription factor involved in the oxidative stress pathway.\",\n      \"method\": \"X-ray crystallography, in vitro transcription assays, mutagenesis of redox-sensing cysteines, cell-based oxidative stress assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with functional mutagenesis and cell-based validation, multiple orthogonal methods\",\n      \"pmids\": [\"26638071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The soy isoflavone daidzein specifically stimulates BRF2 expression in ER-positive breast cancer cells through two mechanisms: stabilization of BRF2 mRNA and selective demethylation of the BRF2 promoter. BRF2 induction is accompanied by increased levels of BRF2-regulated non-coding RNAs. These effects are ER-dependent, as they are absent in ER-negative breast cancer cells.\",\n      \"method\": \"qRT-PCR, western blotting, mRNA stability assays, promoter methylation analysis, 5-azacytidine demethylation experiments\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (mRNA stability, methylation, rescue with demethylating agent), single lab\",\n      \"pmids\": [\"26573593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRF2 acts as a master switch of the oxidative stress response and interplays with the Nrf2/Keap1 pathway. The redox-sensing module of BRF2 integrates oxidative stress signals to regulate Pol III transcription, placing BRF2 downstream of or in parallel with Nrf2/Keap1 signaling.\",\n      \"method\": \"Review/synthesis of structural and functional data (based on prior experimental work from PMID:26638071)\",\n      \"journal\": \"Transcription\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing prior experimental findings; no new primary experiments\",\n      \"pmids\": [\"28854119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRF2 promotes LUAD cell proliferation and metastasis via the MAPK/ERK signaling pathway. Let-7b-3p directly targets the 3' UTR of BRF2 mRNA to suppress its expression, and BRF2 knockdown phenocopies let-7b-3p overexpression. Transcriptome sequencing and western blot analyses confirmed BRF2-mediated activation of MAPK/ERK signaling.\",\n      \"method\": \"Dual-luciferase reporter assay (miRNA target validation), transcriptome sequencing, western blotting, MTT/colony formation/Transwell assays, in vivo xenograft\",\n      \"journal\": \"Translational lung cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by luciferase assay, transcriptome sequencing, in vivo rescue, single lab\",\n      \"pmids\": [\"34012797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRF2 is a novel player in the DNA damage response pathway. BRF2 overexpression promotes cancer cell survival under oxidative stress, and treatment with bexarotene reduces oxidative stress-induced BRF2 levels, decreasing cellular proliferation. BRF2 binds the TBP-DNA complex, and virtual screening identified compounds disrupting the BRF2-TBP-DNA interface.\",\n      \"method\": \"Virtual screening, molecular dynamics simulation, cell viability assays, western blotting with oxidative stress induction (tBHQ)\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3-4 — primarily computational with limited cell-based validation, single lab, no direct mechanistic reconstitution of DNA damage role\",\n      \"pmids\": [\"34359683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MALAT1 acts as a competitive endogenous RNA (ceRNA) to sponge miR-1-3p, thereby upregulating BRF2 expression in HCC. BRF2 knockdown inhibits HCC progression by activating the LKB1/AMPK signaling pathway, and BRF2 overexpression reverses the inhibitory effects of MALAT1 knockdown.\",\n      \"method\": \"Dual-luciferase reporter assay, qRT-PCR, western blotting, CCK-8/colony formation/Transwell assays, flow cytometry, xenograft tumor model\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ceRNA mechanism validated by luciferase assay, pathway confirmed by western blot and rescue experiments, in vivo validation\",\n      \"pmids\": [\"37653482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRF2 promotes HCC invasion and metastasis through the Wnt/β-catenin signaling pathway. miR-409-3p was identified as binding to the 3' UTR of BRF2 and downregulating its expression. BRF2 depletion suppressed HCC metastasis and invasion.\",\n      \"method\": \"Luciferase activity assay (miRNA target validation), bioinformatic pathway analysis, siRNA knockdown, invasion/migration assays\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — Wnt/β-catenin link is bioinformatic only; direct mechanistic link between BRF2 and pathway not experimentally established beyond knockdown phenotype\",\n      \"pmids\": [\"36927769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Biallelic loss-of-function variants in BRF2 cause a novel neurodevelopmental syndrome with craniofacial anomalies and perinatal death. In silico 3D modeling and functional analyses showed that patient variants impair BRF2-dependent RNA Pol III transcription (altered target loci occupancy). Zebrafish brf2 knockdown recapitulated craniofacial malformations and behavioral deficits, which were rescued by wild-type human BRF2 mRNA but not mutant mRNA.\",\n      \"method\": \"Whole-exome sequencing, in silico 3D structural modeling, ChIP/occupancy assays (target loci), zebrafish morpholino knockdown with mRNA rescue\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (structural modeling, functional occupancy assays, zebrafish rescue with wild-type vs. mutant mRNA), independent families\",\n      \"pmids\": [\"40229899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Biallelic BRF2 variants causing multisystem anomalies and primary immunodeficiency disrupt BRF2-dependent RNA Pol III transcription of redox-regulating genes GPX1 and GPX4 (glutathione peroxidases), establishing a pathogenic link between BRF2 dysfunction and disrupted redox homeostasis. Compound heterozygous variants are predicted to disrupt BRF2 interaction with TBP.\",\n      \"method\": \"Whole-exome sequencing, single-cell RNA sequencing, functional analysis of BRF2-dependent Pol III transcription in patient cells, western blotting\",\n      \"journal\": \"Molecular therapy : the journal of the American Society of Gene Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional transcription assay in patient cells identifying specific target genes (GPX1/GPX4), single family/lab\",\n      \"pmids\": [\"40781771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of the full-length SNAPc-containing RNA Pol III pre-initiation complex (PIC) assembled on the U6 snRNA promoter in open and melting states (3.2–4.2 Å resolution) revealed the molecular architecture of the Brf2-containing TFIIIB complex within the PIC. Comparative analysis revealed unexpected structural differences from the yeast PIC and defined the molecular basis of selective, structurally distinct SNAPc engagement within Pol III versus Pol II PICs. Crosslinking mass spectrometry localized SNAPC2 and SNAPC5 subunits in proximity to the promoter DNA.\",\n      \"method\": \"Cryo-EM structure determination, crosslinking mass spectrometry, comparative structural analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures at high resolution with crosslinking MS orthogonal validation\",\n      \"pmids\": [\"bio_10.1101_2024.09.10.612236\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BRF2 (TFIIB-related factor 2) is a vertebrate-specific subunit of the TFIIIB-alpha complex that recruits RNA Polymerase III to type III gene-external promoters (including U6 snRNA and selenocysteine tRNA genes) through TBP-dependent binding to TATA-box elements; it harbors a redox-sensing disulfide module that specifically upregulates Pol III transcriptional output under oxidative stress, placing BRF2 as a central integrator of the Nrf2/Keap1 oxidative stress pathway, and its genetic amplification drives oncogenic transformation by increasing Pol III-mediated small RNA synthesis, while loss-of-function biallelic variants impair transcription of redox-protective genes (GPX1/GPX4) causing neurodevelopmental syndromes with craniofacial anomalies and immunodeficiency.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BRF2 is a vertebrate-specific TFIIB-related subunit of TFIIIB that directs RNA Polymerase III transcription from gene-external (type III) promoters, including U6 snRNA and selenocysteine tRNA genes. Identified as the defining component of TFIIIB-alpha, BRF2 is recruited to TATA-box elements through direct interaction with TBP, stabilizing TBP binding and extending the DNA footprint to nucleate pre-initiation complex assembly [PMID:11121026, PMID:11564744]. Crystal structures of the BRF2–TBP–DNA complex revealed a redox-sensing module within BRF2 that modulates Pol III transcriptional output in response to oxidative stress, and BRF2-dependent transcription of redox-regulating selenoprotein genes (GPX1, GPX4) is impaired by pathogenic biallelic variants, linking BRF2 loss-of-function to a multisystem neurodevelopmental disorder [PMID:26638071, PMID:40781771, PMID:40229899]. BRF2 overexpression drives oncogenic transformation in lung squamous cell carcinoma cells by upregulating Pol III-transcribed snRNAs, and its activity is negatively regulated by MAF1 [PMID:20668658, PMID:17505538].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"The discovery of BRF2 as a distinct TFIIB-family member resolved how human cells assemble a dedicated TFIIIB complex (TFIIIB-alpha) for gene-external Pol III promoters, separate from BRF1-containing TFIIIB-beta used at gene-internal promoters.\",\n      \"evidence\": \"Biochemical reconstitution and in vitro transcription with recombinant BRF2, TBP, and TFIIIB150\",\n      \"pmids\": [\"11121026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BRF2–TBP interaction not yet determined\", \"In vivo validation of TFIIIB-alpha assembly not shown\", \"Full set of BRF2-dependent target genes unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping the BRF2–TBP–DNA interaction established that BRF2 is directly recruited to the TATA box and stabilizes TBP binding, extending the promoter footprint and clarifying how the pre-initiation complex is nucleated at type III Pol III promoters.\",\n      \"evidence\": \"DNase I footprinting, gel shift assays, and domain mutagenesis on snRNA gene promoters\",\n      \"pmids\": [\"11564744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How downstream factors (Pol III, SNAPc) are recruited after BRF2–TBP assembly remained unresolved\", \"Whether BRF2 contacts DNA directly or exclusively through TBP was not fully distinguished\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that MAF1 represses Pol III transcription through BRF2 (and BRF1) identified BRF2 as a regulated node in the Pol III pathway, subject to signal-dependent negative control.\",\n      \"evidence\": \"In vivo Pol III luciferase reporter assay showing MAF1-dependent repression through BRF2\",\n      \"pmids\": [\"17505538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between MAF1 and BRF2 not biochemically characterized\", \"Physiological signals controlling MAF1–BRF2 axis not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing that BRF2 overexpression transforms human bronchial epithelial cells and that BRF2 knockdown suppresses squamous cell carcinoma growth established BRF2 as an oncogenic driver acting through elevated Pol III transcription of snRNAs.\",\n      \"evidence\": \"Gain- and loss-of-function experiments, colony formation assays, and integrative genomic analysis of lung SqCC cohorts\",\n      \"pmids\": [\"20668658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BRF2 oncogenicity depends on specific Pol III transcripts versus global Pol III elevation was not resolved\", \"Mechanism of BRF2 gene amplification or activation in cancer not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of BRF2–TBP on natural promoters uncovered a redox-sensing module in BRF2 that couples oxidative stress to Pol III transcriptional regulation, providing a structural mechanism by which environmental signals directly control the basal Pol III machinery.\",\n      \"evidence\": \"X-ray crystallography of BRF2–TBP–DNA complexes combined with functional assays in living cells\",\n      \"pmids\": [\"26638071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the reactive cysteine(s) and the chemical nature of the redox switch not fully defined\", \"In vivo relevance of redox sensing under physiological ROS levels not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of biallelic BRF2 variants in patients with neurodevelopmental anomalies, combined with impaired transcription of GPX1/GPX4 and rescue of zebrafish craniofacial/neurological defects by wild-type but not mutant BRF2, established BRF2 loss-of-function as a cause of human Mendelian disease linked to disrupted redox homeostasis.\",\n      \"evidence\": \"Whole-exome sequencing of affected families, functional assays in human cells with patient variants, zebrafish morpholino knockdown with mRNA rescue\",\n      \"pmids\": [\"40781771\", \"40229899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full phenotypic spectrum of BRF2 deficiency in humans not delineated\", \"Whether disease pathogenesis is primarily due to redox imbalance or broader Pol III target deficiency is unresolved\", \"Genotype–phenotype correlations across different variant types not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRF2's redox-sensing module integrates with upstream signaling pathways and MAF1-mediated repression to fine-tune Pol III output under physiological and pathological conditions remains mechanistically unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of a complete BRF2-containing Pol III PIC from peer-reviewed literature\", \"Comprehensive identification of BRF2-dependent Pol III target genes in vivo is lacking\", \"Mechanism by which BRF2 overexpression selectively drives oncogenesis in specific tissue types is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 4]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 0]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 2, 4, 8]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"complexes\": [\n      \"TFIIIB-alpha\"\n    ],\n    \"partners\": [\n      \"TBP\",\n      \"BDP1\",\n      \"MAF1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"BRF2 is a vertebrate-specific subunit of the TFIIIB-α complex that, together with TBP and BDP1, directs RNA Polymerase III to gene-external (type III) promoters including U6 snRNA and selenocysteine tRNA genes, thereby controlling the synthesis of essential small non-coding RNAs [PMID:11121026, PMID:11564744]. BRF2 binds DNA-bound TBP in a TATA-box-dependent manner, extending the TBP footprint to stabilize the pre-initiation complex, and harbors a redox-sensing disulfide module whose oxidation-state switch specifically upregulates Pol III transcriptional output under oxidative stress, functionally linking it to the Nrf2/Keap1 pathway [PMID:26638071]. Focal amplification of BRF2 at 8p12 acts as a lineage-specific oncogene in lung squamous cell carcinoma by increasing Pol III-dependent snRNA synthesis, and BRF2 overexpression promotes proliferation and metastasis in additional cancer types through MAPK/ERK and other signaling axes [PMID:20668658, PMID:34012797]. Biallelic loss-of-function BRF2 variants cause a neurodevelopmental syndrome with craniofacial anomalies, immunodeficiency, and impaired transcription of redox-protective genes GPX1 and GPX4 [PMID:40229899, PMID:40781771].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of BRF2 as a second TFIIB-related factor in humans resolved how vertebrate RNA Pol III discriminates between gene-internal and gene-external promoter architectures, establishing that two distinct TFIIIB complexes exist.\",\n      \"evidence\": \"Cloning and biochemical reconstitution of TFIIIB-α activity with purified BRF2, TBP, and BDP1 in vitro\",\n      \"pmids\": [\"11121026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on how BRF2 differs from BRF1 at the atomic level\", \"In vivo promoter occupancy not yet demonstrated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstration that BRF2 is recruited to the TATA-box via TBP and stabilizes TBP on DNA defined the minimal assembly pathway of the TFIIIB-α complex on type III promoters.\",\n      \"evidence\": \"DNase I footprinting, gel mobility shift assays, truncation/mutagenesis, and in vitro transcription\",\n      \"pmids\": [\"11564744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of BDP1 in the ternary complex not structurally resolved\", \"No information on how SNAPc coordinates with BRF2-TBP\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that Maf1 represses Pol III transcription through both BRF1 and BRF2 established a conserved negative regulatory mechanism acting at the TFIIIB level.\",\n      \"evidence\": \"RNA Pol III luciferase reporter assays, in vivo transcription assays, co-immunoprecipitation\",\n      \"pmids\": [\"17505538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction between Maf1 and BRF2 not mapped at residue level\", \"Single-lab finding without independent replication\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of BRF2 as a lineage-specific oncogene amplified in lung squamous cell carcinoma established that deregulated Pol III transcription of small RNAs is sufficient to drive cellular transformation.\",\n      \"evidence\": \"Array CGH across >330 clinical samples, ectopic BRF2 expression inducing transformation of bronchial epithelial cells, RNAi knockdown suppressing growth of SqCC cells\",\n      \"pmids\": [\"20668658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Pol III transcript repertoire mediating transformation not defined\", \"Whether BRF2 amplification cooperates with other 8p12 co-amplified genes unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of the BRF2–TBP complex on natural Pol III promoters revealed a redox-sensing disulfide module within BRF2 that regulates Pol III output under oxidative stress, establishing BRF2 as the first transcription factor integrating redox signals directly into Pol III activity.\",\n      \"evidence\": \"X-ray crystallography, cysteine mutagenesis, in vitro transcription, and cell-based oxidative stress assays\",\n      \"pmids\": [\"26638071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the upstream oxidant or reductant that modulates the disulfide in vivo not determined\", \"Whether the redox switch operates at all BRF2-dependent promoters or selectively is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that daidzein induces BRF2 expression through mRNA stabilization and promoter demethylation in ER-positive breast cancer cells revealed an estrogen receptor-dependent epigenetic axis controlling BRF2 levels.\",\n      \"evidence\": \"mRNA stability assays, promoter methylation analysis, 5-azacytidine rescue in ER-positive vs. ER-negative cell lines\",\n      \"pmids\": [\"26573593\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ER binding to the BRF2 promoter not demonstrated\", \"In vivo relevance of dietary isoflavone exposure to BRF2 regulation not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of miRNA-mediated post-transcriptional regulation of BRF2 (let-7b-3p in LUAD, miR-1-3p via MALAT1 ceRNA in HCC) and downstream signaling through MAPK/ERK and LKB1/AMPK pathways extended the oncogenic role of BRF2 beyond Pol III transcription to broader proliferative and metastatic signaling networks.\",\n      \"evidence\": \"Dual-luciferase target validation, transcriptome sequencing, xenograft models, pathway rescue experiments\",\n      \"pmids\": [\"34012797\", \"37653482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MAPK/ERK activation is a direct or indirect consequence of BRF2-driven Pol III transcript changes is unresolved\", \"The specific Pol III transcripts mediating these signaling effects remain unidentified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that biallelic BRF2 loss-of-function variants cause a neurodevelopmental syndrome with craniofacial anomalies, immunodeficiency, and impaired transcription of GPX1/GPX4 established BRF2 as a Mendelian disease gene and linked its redox-sensing function to human developmental biology.\",\n      \"evidence\": \"Whole-exome sequencing in independent families, ChIP/occupancy assays in patient cells, zebrafish morpholino knockdown rescued by wild-type but not mutant human BRF2 mRNA, single-cell RNA-seq identifying GPX1/GPX4 as affected targets\",\n      \"pmids\": [\"40229899\", \"40781771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of BRF2-dependent Pol III transcripts disrupted in patient cells not catalogued\", \"Whether immunodeficiency is driven by GPX-dependent redox failure or broader Pol III transcript deficiency is unclear\", \"No mouse model yet reported\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the complete repertoire of BRF2-dependent Pol III transcripts in different tissues, the identity of the physiological redox regulators controlling the BRF2 disulfide switch in vivo, and the structural basis of the full human SNAPc–TFIIIB–Pol III pre-initiation complex at atomic resolution.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No published high-resolution structure of the complete human BRF2-containing PIC from a peer-reviewed journal\", \"Tissue-specific BRF2-dependent transcriptome not mapped\", \"Mechanism connecting BRF2 redox state to specific downstream transcript selectivity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140223\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 12, 13]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 5, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 5, 12, 13]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [5, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 8, 10]}\n    ],\n    \"complexes\": [\n      \"TFIIIB-α (BRF2–TBP–BDP1)\"\n    ],\n    \"partners\": [\n      \"TBP\",\n      \"BDP1\",\n      \"MAF1\",\n      \"SNAPC1\",\n      \"SNAPC2\",\n      \"SNAPC5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}